Mirati Therapeutics Inc (MRTX) Jumps 6.09% on February 17

Equities Staff |

Mirati Therapeutics Inc (MRTX) was among the biggest gainers on the Russell 2000 for Wednesday February 17 as the stock popped 6.09% to $22.29, representing a gain of $1.28 per share. Some 295,159 shares traded hands on 2,230 trades, compared with an average daily volume of 179,521 shares out of a total float of 19.27 million. The stock opened at $21.01 and traded with an intraday range of $22.85 to $21.00.

After today's gains, Mirati Therapeutics Inc reached a market cap of $429.44 million. Mirati Therapeutics Inc has had a trading range between $52.00 and $17.94 over the last year, and it had a 50-day SMA of $27.33 and a 200-day SMA of $30.86.

Mirati Therapeutics Inc is a biopharmaceutical company that discovers, develops, and commercializes novel therapeutics with an initial focus on cancer and infectious diseases.

Mirati Therapeutics Inc is based out of San Diego, CA and has some 33 employees. Its CEO is Charles M. Baum.

For a complete fundamental analysis analysis of Mirati Therapeutics Inc, check out Equities.com’s Stock Valuation Analysis report for MRTX. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

PixarBio Corp

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain.

Private Markets

8tracks

Our mission is to be the best place for people who care about music to create and discover thoughtfully curated playlists. In essence, 8tracks is a platform for online mixtapes.

Pinterest

Pinterest is a visual discovery and planning tool. Users ("Pinners") use the site and apps to get ideas for their future, such as recipes, places to travel, and products to…